Jwa68
Nov 21, 4:49 PM
$GANX A day will soon likely come here where the value of @microcapspevulator's past posts will become very self evident and seen as having been incredibly fortelling.
Right aside of the comments of Ray Blanco who recommended
$NVDA at
$3, and
$ABCL, Thomas Shrader (BTIG), Raghuram Selvaraju (H.C. Wainwright & Co.), Jason McCarthy (Maxim Group), Jay Olson (Oppenheimer & Co.), Boobalan Pachaiyappan (Roth) and Louise Chen at Scotia Bank who went as far as to call Gain a possible 🦄.
Anyone taking the time to read and comprehend posts like this and others, can only better understand and appreciate the uniqueness of what rexacerat likely means to not just PD, but to the advancement of medical science and many other correlated diseases. There has never been a drug like it in history, a new science, both a blessing and a curse as a shareholder.
The wave takes longer to build and crest, but when it does, it is a tsunami.
Pharma is most interested in biomarkers, it appears Gain may have yet more coming.
If pharma wants biomarkers, and Gain has them, then is it not logical to suspect pharma may too want Gain and the only available phase 2 ready safe and well tolerated PD asset that works on both GBA-1 and idiopathic, halts the progression of the disease, returns gate, balance and smell, is neuroprotective, and improves mitochondrial and lysomal health, central to aging.
Again...asking for a friend.
Ignore what I post and others here if you choose. We are all admittedly bias by our investments.
That said, the growing list of respected, educated and accredited subject matter experts is growing at a nice clip. Do your own dd as always.
3 replies